Detection of effective treatment of amnestic mild cognitive impairement with cereton by testing of lipids markers

Alesenko A.V.; Gavrilova S.I.; Gutner U.A.; Lebedeva A.O.; Shupik M.A.; Kolykhalov I.V.; Ponomareva E.V.; Selezneva N.D.; Fedorova Ia.B.

doi:https://doi.org/10.17116/jnevro20171176121-27

Alesenko A.V.

Emanuel Institute of Biochemical Physics of RAS, Moscow, Russia

Gavrilova S.I.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

SPIN RSCI: 6094-4303
Scopus AuthorID: 7004829216
ResearcherID: B-4548-2016
ORCID: 0000-0001-6683-0240

Gutner U.A.

Emanuel Institute of Biochemical Physics of RAS, Moscow, Russia

Lebedeva A.O.

Emanuel Institute of Biochemical Physics of RAS, Moscow, Russia

Shupik M.A.

Emanuel Institute of Biochemical Physics of RAS, Moscow, Russia

Kolykhalov I.V.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

ORCID: 0000-0002-2358-1579

Ponomareva E.V.

Otdel geriatricheskoĭ psikhiatrii, otdelenie bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv FGBU "Nauchnyĭ tsentr psikhicheskogo zdorov'ia" RAMN, Moskva

Selezneva N.D.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

Fedorova Ia.B.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

Detection of effective treatment of amnestic mild cognitive impairement with cereton by testing of lipids markers

Authors:

Alesenko A.V., Gavrilova S.I., Gutner U.A., Lebedeva A.O., Shupik M.A., Kolykhalov I.V., Ponomareva E.V., Selezneva N.D., Fedorova Ia.B.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(6): 21‑27

DOI: 10.17116/jnevro20171176121-27

Read: 7837 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Alesenko AV, Gavrilova SI, Gutner UA, et al. Detection of effective treatment of amnestic mild cognitive impairement with cereton by testing of lipids markers. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(6):21‑27. (In Russ.)
https://doi.org/10.17116/jnevro20171176121-27

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

Abstract:

Objective. Determination of effectivity and safety of Cereton (Choline alfoscerate, production by Sotex) 1200 mg/day in the treatment of cognitive functioning disorders in patients with amnestic mild cognitive impairment (aMCI) and determining its influence in the process (after a 3 month course of taking the drug) and 3 months after the end of treatment of aMCI on the change in the content of phosphatidylcholine, sphingomyelin, ceramide-metabolite sphingolipids and the activity of genes controlling the synthesis of enzymes, which control ithe metabolism of sphingomyelin and ceramide (sphingomyelinase and ceramidase). Material and methods. The study involved a group of elderly patients (20 people), consisting of 14 women and 6 men, aged 51 to 82 years (mean age 70.3±9.1 years). The patients’ condition met the criteria for diagnosing aMCI syndrome. Analysis of phosphatidylcholine, sphingomyelin and ceramide in the blood plasma of patients was carried out by thin layer chromatography, expression of sphingomyelinase and ceramidase genes by RtPCR. Results and conclusion. A sharp increase in the content of phosphatidylcholine and ceramide, the product of sphingomyelin hydrolysis, was detected. Expression of genes (acidic sphingomyelinase and ceramidase), controlling the metabolism of ceramide, is significantly reduced in the majority of patients in the treatment with ceretone. An increase in the level of phosphatidylcholine and a decrease in the expression level of the ceramide metabolism genes during treatment with ceretone and other drugs that affect the metabolism of phosphatidylchodine and sphingolipids can be used as markers of the effectiveness of therapy.

Keywords:

mild cognitive impairement (MCI)

phosphatidylcholine

sphingomyelin

ceramide

sphingomyelinase

ceramidase

Authors:

Alesenko A.V.

Emanuel Institute of Biochemical Physics of RAS, Moscow, Russia

Gavrilova S.I.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

SPIN RSCI: 6094-4303
Scopus AuthorID: 7004829216
ResearcherID: B-4548-2016
ORCID: 0000-0001-6683-0240

Gutner U.A.

Emanuel Institute of Biochemical Physics of RAS, Moscow, Russia

Lebedeva A.O.

Emanuel Institute of Biochemical Physics of RAS, Moscow, Russia

Shupik M.A.

Emanuel Institute of Biochemical Physics of RAS, Moscow, Russia

Kolykhalov I.V.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

ORCID: 0000-0002-2358-1579

Ponomareva E.V.

Otdel geriatricheskoĭ psikhiatrii, otdelenie bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv FGBU "Nauchnyĭ tsentr psikhicheskogo zdorov'ia" RAMN, Moskva

Selezneva N.D.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

Fedorova Ia.B.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

Close metadata

References:

Rukovodstvo po geriatricheskoj psihiatrii. Pod red. Gavrilovoj S.I. M.: Pul’s; 2011. (In Russ.) .
Kalyn YaB, Gavrilova SI. Dinamika pokazatelej rasprostranennosti psihicheskih rasstrojstv v naselenii pozhilogo i starcheskogo vozrasta. Reformy sluzhby psihicheskogo zdorov’ya: problemy i perspektivy. 1997;181-189. (In Russ.) .
Selezneva ND, Mihajlova NM, Kalyn YaB, Roshchina IF, Gavrilova SI. Issledovanie ehffektivnosti i bezopasnosti primeneniya aktovegina u bol’nyh pozhilogo vozrasta s sindromom myagkogo kognitivnogo snizheniya cerebral’no-sosudistogo geneza. Psihiatriya. 2009;1:37-50. (In Russ.) .
Gavrilova SI, Kolyhalov IV, Fedorova JaB, Selezneva ND, Kalyn JaB, Roshhina IF, Odinak MM, Emelin AJu, Kashin AV, Gustov AV, Antipenko EA, Korshunova JuA, Davydova TA, Messler G. Vozmozhnosti preventivnoj terapii bolezni Al’cgejmera: rezul’taty 3-letnego prospektivnogo otkrytogo sravnitel’nogo issledovanija jeffektivnosti i bezopasnosti kursovoj terapii cerebrolizinom i kavintonom u pozhilyh pacientov s sindromom mjagkogo kognitivnogo snizhenija. Zh. Nevrologii i psihiatrii im. S.S. Korsakova. 2010;1:68-75. (In Russ.) .
Adibhatla RM, Hatcher JF. Altered lipid metabolism in brain injury and disorders. Subcell Biochem. 2008;49:241-268. https://doi.org/10.1007/978-1-4020-8831-5_9
Colombaioni L, Garcia-Gil M. Sphingolipid metabolites in neural signalling and function. Brain Res Brain Res Rev. 2004;46:328-355. https://doi.org/10.1016/j.brainresrev.2004.07.014
Alessenko AV, Gurianova SV. Potential role of ceramides in neurodegenerative diseases. In: Sphingomyelin and Ceramides: Occurance, Biosynthesis and Role in Disease. NOVA Sci Publisher, NY, USA. 2015;P. 21-53.
Ban TA, Panzarasa RM, Borra S, Del Duchetto D, Fjetland OK. Choline alphoscerate in elderly patients with cognitive decline due to dementing illness. New Trends of Clinical Neuropharmacology. 1991;5:1-35.
Shavlovskaja OA. Opyt primenenija preparata cereton (holinaal’foscerat) v klinicheskoj praktike. Rus med zhurn. 2011;19(9):557-561. (In Russ.) .
Parnetti L, Abate G, Bartorelli L, Cucinotta D, Cuzzupoli M, Maggioni M, Villardita C, Senin U. Multicentre study of 1-alpha-glycerylphosphorylcholine vs ST 200 among patients with probable senile dementia of Alzheimer type. Drug and Aging. 1993;3(suppl 2):159-164. https://doi.org/10.2165/00002512-199303020-00006
Aguglia E, Ban TA, Panzarasa RM, Borra S, Fietland OK. Choline alphoscerate in the treatment of mental pathology following acute cerebrovascular accident. Functional Neurology. 1993;8(suppl 3):5-24.
Scapicchio PL. Revisiting choline alphoscerato profile: a new perspective role in dementia. Int J Neurosci. 2013;123:444-449. https://doi.org/10.3109/00207454.2013.765870
Bujlova TV, Glotova ME, Halak ME, Vashkevich VV. Opyt primenenija Ceretona v processe reabilitacii bol’nyh s gemorragicheskim insul’tom. Zhurn nevrologii i psihiatrii im. S.S. Korsakova. 2009;5(2):58-62. (In Russ.) .
Gavrilova SI, Alessenko AV, Kolykhalov IV, Fedorova YB, Selezneva ND, Ponomareva EV, Gurianova SV, Gutner UA, Shupik MA. Clinical and biological effects of Cereton in the treatment of amnestic mild cognitive impairment. Psichiatry. 2017;73(1):5-15. (In Russ.) .
Bligh TG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 37:911-917. https://doi.org/10.1139/o59-099
Duan RD. Alkaline sphingomyelinase: an old enzyme with novel implications. Biochim Biophys Acta. 2006;1761:281-291. https://doi.org/10.1016/j.bbalip.2006.03.007
Jenkins RW, Canals D, Hannun YA. Roles and regulation of secretory and lysosomal acid sphingomyelinase. Cell Signal. 2009;21:836-846.
Yu ZF, Nikolova-Karakahian M, Zhou D, Cheng G, Schuchman EH, Mattson MP. Pivotal role for acidic sphingomyelinase in cerebral ischemias-induced ceramide and cytokine production, and neuronal apoptosis. J Mol Neurosci. 2000;15:85-97. https://doi.org/10.1385/JMN:15:2:85
Bartke N, Hannun YA. Bioactive sphingolipids: metabolism and functions. J lipid Res. 2009;50(suppl):91-96. https://doi.org/10.1194/jlr.R800080-JLR200
Maceyka M., Harikumar KB, Milstein S, and Spiegel S. Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol. 2012;22:50-60. https://doi.org/10.1016/j.tcb.2011.09.003
Mao C, Obeid LV. Ceramidases: regulators of cellular responses mediated by ceramide, sphingosine, and sphingosine-1-phosphate. Biochim Biophys Acta. 2008;1781:424-434. https://doi.org/10.1016/j.bbalip.2008.06.002
Katsel P, Li C, Haroutunian V. Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer’s disease: A shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer’s disease? Neurochem Res. 2007;32:845-856. https://doi.org/10.1007/s11064-007-9297-x